{"id":"W2562028759","doi":"10.1093/annonc/mdv340.05","title":"Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; FOLFIRI; Ramucirumab; Internal medicine; Clinical endpoint; Irinotecan; Bevacizumab; Progression-free survival; Hazard ratio; KRAS; Oncology; Population; Fluorouracil; Adverse effect; Colorectal cancer; Randomized controlled trial; Chemotherapy; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004930399,0.0008894382,0.00689154,0.001288875,0.0004049636,0.00134291,0.001409773,0.00125073,0.003538567],"category_scores_gemma":[0.01029215,0.0005431584,0.003375446,0.001779864,0.000539755,0.000777493,0.0003977669,0.001116119,0.0006729112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001690276,"about_ca_system_score_gemma":0.002735869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002959504,"about_ca_topic_score_gemma":0.008485007,"domain_scores_codex":[0.9984539,0.0006014524,0.0004659514,0.0001903865,0.0002395127,0.00004887478],"domain_scores_gemma":[0.9946582,0.003158791,0.001302886,0.0001323987,0.0005720792,0.0001756176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.01831735,0.0001339576,0.0007701771,0.7607287,0.03511972,0.0002131189,0.0002350725,0.000192407,0.001824005,0.0005643431,0.03414181,0.1477594],"study_design_scores_gemma":[0.06637333,0.008194236,0.0220102,0.2564806,0.3648722,0.001364708,0.0005284972,0.0004148909,0.002275417,0.001408023,0.275876,0.0002019378],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.00453957,0.9882755,0.0004214245,0.001837549,0.001333746,0.000726326,0.001515744,0.00003950691,0.001310568],"genre_scores_gemma":[0.06048584,0.9224088,0.001377552,0.009650526,0.001430764,0.001024933,0.001612515,0.0000389141,0.001970185],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.00689154,"threshold_uncertainty_score":0.02607471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08266802494232954,"score_gpt":0.3826142284964277,"score_spread":0.2999462035540982,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}